Denali Therapeutics Inc (NASDAQ:DNLI) insider Carole Ho sold 3,689 shares of Denali Therapeutics stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $31.00, for a total transaction of $114,359.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Shares of NASDAQ:DNLI opened at $37.27 on Wednesday. Denali Therapeutics Inc has a 12 month low of $12.39 and a 12 month high of $37.82. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.57 and a quick ratio of 9.57. The business’s 50 day simple moving average is $30.23 and its 200-day simple moving average is $24.42. The firm has a market capitalization of $3.95 billion, a price-to-earnings ratio of -17.33 and a beta of 1.91.
Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.05. Denali Therapeutics had a negative net margin of 778.32% and a negative return on equity of 45.90%. On average, equities analysts anticipate that Denali Therapeutics Inc will post 1.4 earnings per share for the current year.
DNLI has been the topic of a number of recent analyst reports. ValuEngine lowered shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 1st. Zacks Investment Research cut shares of Denali Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 13th. Morgan Stanley raised their price target on shares of Denali Therapeutics from $28.00 to $45.00 and gave the stock an “overweight” rating in a research report on Monday, August 24th. TheStreet raised shares of Denali Therapeutics from a “d+” rating to a “c-” rating in a report on Wednesday, May 20th. Finally, Wedbush reiterated an “outperform” rating on shares of Denali Therapeutics in a research report on Monday, August 10th. Five equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $33.36.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.
Further Reading: VIX – Volatility Index
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.